よむ、つかう、まなぶ。
会議資料 (130 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/shingi2/0000198856_00045.html |
| 出典情報 | 医療上の必要性の高い未承認薬・適応外薬検討会議（第67回 2／6）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
（公知申請への該当性に係る企業見解の様式）
要望番号；IV-140
allogeneic peripheral blood stem cell transplant vs bone marrow transplant in the management
of hematological malignancies: indirect assessment of the effect of day 11 methotrexate
administration. Bone Marrow Transplant 2006;38(8):539-46.
28. Ram R, Gafter-Gvili A, Yeshurun M, et al. Prophylaxis regimens for GVHD: systematic review
and meta-analysis. Bone Marrow Transplant 2009;43(8):643-53.
29. Kharfan-Dabaja MA, Reljic T, Kumar A, et al. Omission of day +11 methotrexate dose and
allogeneic hematopoietic cell transplantation outcomes: results of a systematic review/metaanalysis. Bone Marrow Transplant 2022;57(1):65-71.
30. Appelbaum FR. Harrison's Principles of Internal Medicine, 20e, Chapter 110: Hematopoietic
Cell Transplantation. McGraw-Hill, 2021.
31. Forman SJ, Negrin RS, Antin JH, et al. Thomas' Hematopoietic Cell Transplantation Stem Cell
Transplantation. 5th Ed, Wiley Blackwell; 2016.
32. Kaushansky K, Lichtman MA, Prchal JT, et al. Williams Hematology. 9th ed. McGrawHill;2016.
33. Greer JP, Arber DA, Glader BE, et al. Wintrobe's Clinical Hematology. 14th ed. Wolters Kluwer,
2019.
34. 造血幹細胞移植の基礎と臨床 改訂 3 版 神田善伸編, p465.
35. GVHD（移植片対宿主病）の基礎と臨床 豊嶋崇徳編, p208-11.
36. 日本造血・免疫細胞療法学会. 造血細胞移植ガイドライン GVHD（第 6 版）2025.
37. Kanda J, Brazauskas R, Hu Z-H, et al. Graft-versus-Host Disease after HLA-Matched Sibling
Bone Marrow or Peripheral Blood Stem Cell Transplantation: Comparison of North American
Caucasian and Japanese Populations. Biol Blood Marrow Transplant 2016;22(4):744-51.
38. Terakura S, Atsuta Y, Tsukada N, et al. Comparison of Outcomes of 8/8 and 7/8 Allele-Matched
Unrelated Bone Marrow Transplantation and Single-Unit Cord Blood Transplantation in Adults
with Acute Leukemia. Biol. Blood Marrow Transplant 2016;22(2):330-8.
39. Tomizawa D, Tanaka S, Kondo T, et al. Allogeneic Hematopoietic Stem Cell Transplantation for
Adolescents and Young Adults with Acute Myeloid Leukemia. Biol Blood Marrow Transplant
2017;23(9):1515-22.
40. Kawahara Y, Morimoto A, Inagaki J, et al. Unrelated cord blood transplantation with
myeloablative conditioning for pediatric acute lymphoblastic leukemia in remission: prognostic
factors. Bone Marrow Transplant 2021;56(2):357-67.
41. Matsuyama T, Kojima S, Kato K. Allogeneic bone marrow transplantation for childhood
leukemia following a busulfan and melphalan preparative regimen. Bone Marrow Transplant
1998;22(1):21-6.
42. Hamazaki T, Yagi K, Inoue M, et al. [Prophylaxis with FK-506 for graft-versus-host disease after
transplantation of bone marrow from unrelated donors] [Japanese]. Rinsho Ketsueki
2000;41(5):430-6.
31
130 / 230
要望番号；IV-140
allogeneic peripheral blood stem cell transplant vs bone marrow transplant in the management
of hematological malignancies: indirect assessment of the effect of day 11 methotrexate
administration. Bone Marrow Transplant 2006;38(8):539-46.
28. Ram R, Gafter-Gvili A, Yeshurun M, et al. Prophylaxis regimens for GVHD: systematic review
and meta-analysis. Bone Marrow Transplant 2009;43(8):643-53.
29. Kharfan-Dabaja MA, Reljic T, Kumar A, et al. Omission of day +11 methotrexate dose and
allogeneic hematopoietic cell transplantation outcomes: results of a systematic review/metaanalysis. Bone Marrow Transplant 2022;57(1):65-71.
30. Appelbaum FR. Harrison's Principles of Internal Medicine, 20e, Chapter 110: Hematopoietic
Cell Transplantation. McGraw-Hill, 2021.
31. Forman SJ, Negrin RS, Antin JH, et al. Thomas' Hematopoietic Cell Transplantation Stem Cell
Transplantation. 5th Ed, Wiley Blackwell; 2016.
32. Kaushansky K, Lichtman MA, Prchal JT, et al. Williams Hematology. 9th ed. McGrawHill;2016.
33. Greer JP, Arber DA, Glader BE, et al. Wintrobe's Clinical Hematology. 14th ed. Wolters Kluwer,
2019.
34. 造血幹細胞移植の基礎と臨床 改訂 3 版 神田善伸編, p465.
35. GVHD（移植片対宿主病）の基礎と臨床 豊嶋崇徳編, p208-11.
36. 日本造血・免疫細胞療法学会. 造血細胞移植ガイドライン GVHD（第 6 版）2025.
37. Kanda J, Brazauskas R, Hu Z-H, et al. Graft-versus-Host Disease after HLA-Matched Sibling
Bone Marrow or Peripheral Blood Stem Cell Transplantation: Comparison of North American
Caucasian and Japanese Populations. Biol Blood Marrow Transplant 2016;22(4):744-51.
38. Terakura S, Atsuta Y, Tsukada N, et al. Comparison of Outcomes of 8/8 and 7/8 Allele-Matched
Unrelated Bone Marrow Transplantation and Single-Unit Cord Blood Transplantation in Adults
with Acute Leukemia. Biol. Blood Marrow Transplant 2016;22(2):330-8.
39. Tomizawa D, Tanaka S, Kondo T, et al. Allogeneic Hematopoietic Stem Cell Transplantation for
Adolescents and Young Adults with Acute Myeloid Leukemia. Biol Blood Marrow Transplant
2017;23(9):1515-22.
40. Kawahara Y, Morimoto A, Inagaki J, et al. Unrelated cord blood transplantation with
myeloablative conditioning for pediatric acute lymphoblastic leukemia in remission: prognostic
factors. Bone Marrow Transplant 2021;56(2):357-67.
41. Matsuyama T, Kojima S, Kato K. Allogeneic bone marrow transplantation for childhood
leukemia following a busulfan and melphalan preparative regimen. Bone Marrow Transplant
1998;22(1):21-6.
42. Hamazaki T, Yagi K, Inoue M, et al. [Prophylaxis with FK-506 for graft-versus-host disease after
transplantation of bone marrow from unrelated donors] [Japanese]. Rinsho Ketsueki
2000;41(5):430-6.
31
130 / 230